Literature DB >> 11433126

Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate.

W B White1.   

Abstract

The incidence of most adverse cardiovascular events appears to follow a circadian pattern, reaching a peak in the morning shortly after wakening and arising. The activities of many physiologic parameters, including hemodynamic, hematologic and humoral factors, also fluctuate in a cyclical manner over the 24h. It has been suggested that, during the post-awakening hours, the phases of these cycles synchronize to create an environment that predisposes to atherosclerotic plaque rupture and thrombosis in susceptible individuals, thereby accounting for the heightened cardiovascular risk at this time of day. Blood pressure and heart rate are part of this physiologic process, following a clear circadian rhythm characterized by a fall during sleep and a sharp rise upon awakening. This so-called 'morning surge' in blood pressure may act as a trigger for cardiovascular events, including myocardial infarction and stroke. The clinical implication of these observations is that antihypertensive therapy should provide blood pressure control over the entire interval between doses. For agents taken once daily in the morning, the time of trough plasma drug level (and lowest pharmacodynamic effect) will often coincide with the early morning surge in blood pressure and heart rate. For these reasons, chronotherapeutic formulations of drugs and intrinsically long-acting antihypertensive agents provide the most logical approach to the treatment of hypertensive patients since they provide 24 h blood pressure control from a single daily dose as well as attenuating the early morning rise in blood pressure (and in some instances heart rate).

Entities:  

Mesh:

Year:  2001        PMID: 11433126     DOI: 10.1097/00126097-200104000-00001

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  26 in total

1.  Influence of weather on emergency transport events coded as stroke: population-based study in Japan.

Authors:  Kenji Ohshige; Yuta Hori; Osamu Tochikubo; Mitsugi Sugiyama
Journal:  Int J Biometeorol       Date:  2005-12-20       Impact factor: 3.787

2.  Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect.

Authors:  George Mansour; Janette Mansour
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

3.  Pre-awakening diastolic hypotension in treated hypertensive patients: prevalence and predictors.

Authors:  K H Zheng; E H Serné; A J Kooter; Y M Smulders
Journal:  J Hum Hypertens       Date:  2015-07-23       Impact factor: 3.012

Review 4.  [Blood pressure and the brain].

Authors:  A Hartmann; S Moskau
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

Review 5.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Utility of ambulatory blood pressure monitoring in children and adolescents.

Authors:  John W Graves; Mohammed Mahdi Althaf
Journal:  Pediatr Nephrol       Date:  2006-07-06       Impact factor: 3.714

Review 7.  Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?

Authors:  William B White; Spyridoula Maraka
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

Review 8.  Nocturnal blood pressure, morning blood pressure surge, and cerebrovascular events.

Authors:  Yuichiro Yano; Kazuomi Kario
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 9.  Managing hypertension with ambulatory blood pressure monitoring.

Authors:  William B White; Vinay Gulati
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

Review 10.  Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Authors:  David H G Smith
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.